Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
cyclin-dependent kinase inhibitor |
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EF04
|
| gptkbp:brand |
gptkb:Cosela
|
| gptkbp:CASNumber |
1374743-00-6
|
| gptkbp:chemicalFormula |
C24H30N8O2
|
| gptkbp:developedBy |
gptkb:G1_Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
Trilaciclib
|
| gptkbp:indication |
Small Cell Lung Cancer
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
cell cycle arrest in hematopoietic stem and progenitor cells
|
| gptkbp:molecularWeight |
462.55 g/mol
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fatigue
headache hypokalemia hypophosphatemia hypocalcemia infusion-related reactions |
| gptkbp:synonym |
G1T28
|
| gptkbp:target |
gptkb:CDK4
gptkb:CDK6 |
| gptkbp:UNII |
6QZ7B6W1G3
|
| gptkbp:usedFor |
chemotherapy-induced myelosuppression
|
| gptkbp:bfsParent |
gptkb:GTHX
|
| gptkbp:bfsLayer |
8
|